Immunotherapy in Melanoma Articles | Page 2

Immunotherapy Infuses New Hope Into Merkel Cell Carcinoma Care
While chemotherapy has historically been used to treat patients with Merkel cell carcinoma, immunotherapy advances have infused new hope into the treatment landscape.
FDA Grants Priority Review to Adjuvant Nivolumab in Melanoma
The FDA has granted a priority review to a supplemental biologics license application for nivolumab (Opdivo) to treat patients with melanoma who are at high risk of disease recurrence following complete surgical resection.
Relatlimab/Nivolumab Combo Active in Melanoma After PD-1/PD-L1 Therapy
Half of patients with melanoma who progressed on anti-PD-1/PD-L1 therapy benefited from the combination of nivolumab and the LAG-3 inhibitor relatlimab.
Avelumab Approved in Europe for Merkel Cell Carcinoma
The European Commission has approved avelumab (Bavencio) for the treatment of patients with metastatic Merkel cell carcinoma.
Nivolumab Superior to Ipilimumab as Adjuvant Therapy for Stage III/IV Resected Melanoma
Nivolumab (Opdivo) may represent a new standard option for adjuvant therapy for patients with resected stage IIIB/C and IV melanoma, whether or not they have a BRAF mutation. In a comparison with current standard high-dose ipilimumab (Yervoy), nivolumab demonstrated a significant improvement in relapse-free survival.
Update Confirms Benefit of Pembrolizumab Plus Indoximod in Melanoma
Adding the IDO inhibitor indoximod to pembrolizumab (Keytruda) led to an overall response rate of 61% in patients with advanced melanoma.
Andtbacka Discusses Long-Term Data and Next Steps With T-VEC in Melanoma
Robert Andtbacka, MD, discusses the long-term results for T-VEC in melanoma and the remaining challenges with the oncolytic immunotherapy.
FDA Approves Ipilimumab for Pediatric Melanoma
The FDA has approved ipilimumab for the treatment of patients aged ≥12 years with unresectable or metastatic melanoma.
Avelumab Recommended for EU Approval for Merkel Cell Carcinoma
The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of avelumab (Bavencio) for adults with metastatic Merkel cell carcinoma, according to Pfizer and Merck, the codevelopers of the PD-L1 inhibitor.
Pembrolizumab Demonstrates Long-Term OS Benefit in Advanced Melanoma
Pembrolizumab (Keytruda) provides a long-term survival benefit in both ipilimumab-naïve and ipilimumab-treated patients with advanced melanoma.
Publication Bottom Border
Border Publication